Video: Superheroes, Secret Identities & You| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • Technology
      • Information Technology
      • Apps
    • QA/QI
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
      • Education & Training
    • Certification
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: pain

Complex Treatment: Cancer, Immunotherapy & Rheumatic Disease

Richard Quinn  |  May 6, 2017

Some cancer patients taking immune checkpoint inhibitors experience immune-related adverse events. Laura C. Cappelli, MD, MHS, says rheumatologists are natural partners with oncologists to treat this patient population…

Filed under:ConditionsDrug Updates Tagged with:adverse eventsCancerimmune checkpoint inhibitor (ICI)immune-related adverse eventsimmunotherapy

Noridian Updates Tendon Injections Guidelines for Jurisdiction F

From the College  |  May 3, 2017

Effective May 22, 2017 Noridian has updated the Local Coverage Determination (LCD) coding guidelines for CPT procedures 20552, injection(s); single or multiple trigger point(s), 1 or 2 muscle(s) and 20553, injection(s); single or multiple trigger point(s), 3 or more used to affect therapy for a pathological condition. Noridian states the goal of the updated diagnostic…

Filed under:Billing/CodingPractice SupportProfessional Topics Tagged with:CPT codes 20552 and 20553CPT procedures 20552Jurisdiction FLocal Coverage Determination (LCD) coding guidelinesNoridianTendon Injections Guidelines

FDA to Review Immediate-Release Oxycodone; Plus NICE Recommends Secukinumab

Michele B. Kaufman, PharmD, BCGP  |  May 1, 2017

A new formulation of oxycodone in 10 and 15 mg doses is being reviewed by the FDA for treating pain…

Filed under:AnalgesicsBiologics/DMARDsConditionsDrug UpdatesPsoriatic Arthritis Tagged with:FDAFood and Drug AdministrationOpioidsPsoriatic Arthritissecukinumab

MicroRNAs Provide Insight into Bone Metabolism

Lara C. Pullen, PhD  |  May 1, 2017

A recent study examined the functional variants within microRNAs that affect bone metabolism and possibly bone disorders. Researchers found overexpression of microRNAs may contribute to the osteoporotic phenotype, and the gene targets associated with two specific osteoblast-expressed microRNAs may be critical in osteoporosis…

Filed under:ConditionsOsteoarthritis and Bone Disorders Tagged with:bonemicroRNAOsteoporosisRNAsingle nucleotide polymorphisms

A Moving Target: Cardiovascular Risk & Rheumatic Disease

Richard Quinn  |  April 21, 2017

For patients with rheumatic disease, general treatment guidelines for managing cardiovascular risk are suboptimal, says Katherine Liao, MD. A patient’s level of disease activity and inflammation affect their risk…

Filed under:ConditionsVasculitis Tagged with:cardiovascularheartRheumatic Diseaserheumatologists

Rheumatology Coding Corner Question: Billing Infusion Procedure with JW Modifier

From the College  |  April 20, 2017

An 82-year-old female established patient diagnosed with ankylosing spondylitis in multiple joints returns to the office for her second infliximab infusion. She denies any fevers, cough or concurrent illness. Her joint pain is 7 on a scale of 1–10. She complains of achy pain in the cervical, lumbar and sacral regions of her spine. She…

Filed under:Billing/CodingFrom the CollegePractice Support Tagged with:BillingCodinginfliximabInfusionoffice visitpatient carePractice Managementrheumatologistrheumatology

Rheumatology Case Report: Bullous Lesions in Patient with Lupus

Mitali Sen, MD, Corrado Minimo, MD, & Ruchika Patel, MD  |  April 20, 2017

Systemic lupus erythematosus (SLE) is a heterogeneous disease associated with multiple acute or chronic cutaneous manifestations, including the relatively rare category of bullous lupus. The development of vesiculo-bullous lesions may be associated with a high morbidity, hence they warrant an urgent investigation, including a skin biopsy to identify the diagnosis and initiate prompt treatment. With…

Filed under:ConditionsSystemic Lupus Erythematosus Tagged with:bullous lesioncase reportClinicalcutaneousDiagnosisLupuspatient carerheumatologistrheumatologyscalded skin syndromeSLEstaphylococcalSystemic lupus erythematosusTreatment

Brodalumab Approved for Plaque Psoriasis, Plus Baricitinib Effiicacy Studied for RA

Michele B. Kaufman, PharmD, BCGP  |  April 20, 2017

Brodalumab Approved for Plaque Psoriasis The U.S. Food and Drug Administration has approved brodalumab, a monoclonal antibody that targets interleukin 17 (IL‑17).1,2 Brodalumab (Siliq) was approved for treating moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy and have failed to respond to, or have lost response to, other…

Filed under:ConditionsDrug Updates Tagged with:adalimumabbaricitinibbrodalumabClinicalDrugsefficacyFDAoutcomeplaque psoriasisRheumatoid arthritisrheumatologySafetyTreatment

Fellows Forum Case Report: Neuromyelitis Optica

Atul Kapila, MD, Tayseer Haroun, MBBS, & Jayanth Doss, MD  |  April 19, 2017

Case Presentation The patient was a 42-year-old African American female diagnosed with systemic lupus erythematosus (SLE) based on the findings of polyarthritis, malar and discoid rash, fatigue, positive double-stranded DNA (dsDNA) ribonucleoprotein and Smith antibodies, and low serum complement levels. Her SLE had been well controlled on hydroxychloroquine 400 mg daily, oral methotrexate 25 mg…

Filed under:ConditionsOther Rheumatic Conditions Tagged with:case reportcentral nervous systemClinicalDevic's diseaseDiagnosiseyeFellowsFellows Foruminflammatory syndromeneuromyelitis opticaoutcomerheumatologyTreatmentvision

Straightforward Approach Can Help Rheumatology Health Professionals Engage with Fibromyalgia Patients

Terence Starz, MD, on behalf of the ARHP Practice Committee  |  April 19, 2017

“I have pain all over my body” is a challenging response after you’ve asked a new patient what brings them in for their visit. You immediately suspect that this patient has fibromyalgia. The prevalence of fibromyalgia in the U.S. is 5 million people, and it is among the most common conditions in many rheumatology practices….

Filed under:ConditionsPain SyndromesPractice SupportSoft Tissue Pain Tagged with:Fibromyalgiaoffice visitPainpatient carephysician-patient communicationrheumatologistrheumatologysymptomTreatment

  • « Previous Page
  • 1
  • …
  • 139
  • 140
  • 141
  • 142
  • 143
  • …
  • 243
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences